# Scribe Therapeutics Prices $129M IPO on Nasdaq as First Gene Editing IPO in Over Two Years

> financing · REPORTED · 2026-07-23

Scribe Therapeutics priced its Nasdaq IPO on July 23, 2026, raising approximately $129 million by selling 8.58 million shares at $15 each, making it the first gene editing company to go public in more than two years. The company is developing CRISPR-based genetic medicines for cardiometabolic disorders including lipid-lowering programs, with pharma collaborations with Biogen, Sanofi, and Eli Lilly.

About Scribe Therapeutics: Scribe Therapeutics is a San Francisco Bay Area biotech founded by Nobel laureate Jennifer Doudna that is developing in vivo CRISPR gene editing medicines targeting cardiometabolic diseases such as elevated LDL and Lp(a).

- Company: Scribe Therapeutics
- Sector: biotech
- Primary source: https://www.biopharmadive.com/news/scribe-ipo-price-gene-editing-biotech-pcsk9-lpa/825933/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.